COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW. YHCĐ. 2026;67(10). doi:10.52163/yhc.v67i10.6921